Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin and piperine for ureteral stent-induced symptoms in cancer patients
NCT02598726Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2016
- Primary completion
- Sep 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of curcumin in ureteral stent syndrome (SRS), sponsored by Mayo Clinic. Primary endpoints: Incidence of adverse events at 1 month and Maximum tolerated dose at 7 days. Started Mar 2016; status: completed.
02
Drugs
curcumin
03
Conditions
ureteral stent syndrome (SRS)
Beyond the preview
Go deeper on NCT02598726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598726.